2-methyl-2-(2-methylprop-1-en-1-yl)-3,4-dihydro-2H-benzo[h]chromen-5,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: 2-methyl-2-(2-methylprop-1-en-1-yl)-3,4-dihydro-2H-benzo[h]chromen-5,6-dione
• 英文别名: 2-Methyl-2-(2-methylprop-1-enyl)-3,4-dihydrobenzo[h]chromene-5,6-dione
• 化学式: C₁₈H₁₈O₃
• 分子量: 282.339
• InChiKey: UWTHQTPDYSGISW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-二甲基-1,3-戊二烯 、 聚合甲醛 、 2-羟基-1,4-萘醌 以 1,4-二氧六环 为溶剂， 反应 10.0h， 生成 2-methyl-2-(2-methylprop-1-en-1-yl)-3,4-dihydro-2H-benzo[h]chromen-5,6-dione
  参考文献：
  名称：

  WO2008/66297

  摘要：

  公开号：

文献信息

• [EN] NOVEL PHENAZINE DERIVATIVES AND THEIR USE<br/>[FR] NOUVEAUX DÉRIVÉS DE PHÉNAZINE ET LEUR UTILISATION
  申请人：UNIV CATHOLIQUE LOUVAIN

  公开号：WO2012085222A1

  公开（公告）日：2012-06-28

  The present invention is directed to novel compounds of formula (I) and their use as anti-angiogenic agents and anti-cancer agents.

  本发明涉及式（I）的新化合物及其作为抗血管生成和抗癌剂的用途。
• NOVEL PHENAZINE DERIVATIVES AND THEIR USES
  申请人：Feron Olivier

  公开号：US20130289030A1

  公开（公告）日：2013-10-31

  The present invention is directed to novel compounds of formula I and their use as anti-angiogenic agents and anti-cancer agents.

  本发明涉及一种新型化合物的公式I及其用作抗血管生成和抗癌剂的用途。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE
  申请人：Kwak Taehwan

  公开号：US20100239674A1

  公开（公告）日：2010-09-23

  Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  本发明公开了一种用于治疗和/或预防勃起功能障碍的药物组合物，包括（a）按照式1或式2表示的化合物的治疗有效量，以及（b）药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• Pharmaceutical Composition for the Treatment or Prevention of Diseases Involving Obesity, Diabetes, Metabolic Syndrome, Neuro-Degenerative Diseases and Mitochondria Dyfunction Diseases
  申请人：Yoo Sang-Ku

  公开号：US20080146655A1

  公开（公告）日：2008-06-19

  Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供一种药物组合物，用于治疗和预防肥胖、糖尿病、代谢综合征、退行性疾病和线粒体功能障碍相关疾病，包括：以下式I所表示的化合物的治疗有效量，或其药学上可接受的盐、前药、溶剂或异构体，以及药学上可接受的载体、稀释剂或赋形剂，或其任意组合。
• PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DISEASES INVOLVING OBESITY, DIABETES, METABOLIC SYNDROME, NEURO-DEGENERATIVE DISEASES AND MITOCHONDRIA DYSFUNCTION DISEASES
  申请人：Yoo Sang-Ku

  公开号：US20090292011A1

  公开（公告）日：2009-11-26

  Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.

  提供了一种用于治疗和预防肥胖、糖尿病、代谢综合征、退行性疾病以及线粒体功能障碍相关疾病的制药组合物，包含以下公式I所表示的化合物的治疗有效量，或其药学上可接受的盐、前药、溶剂或异构体，以及药学上可接受的载体、稀释剂或赋形剂，或任何组合。